Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Population Pharmacokinetics of Elagolix in Healthy Women and Women with Endometriosis.

Clinical pharmacokinetics - 1 Oct 2018

Winzenborg Insa, Nader Ahmed, Polepally Akshanth R, Liu Mohan, Degner Jacob, Klein Cheri E, Mostafa Nael M, Noertersheuser Peter, Ng Juki

Abstract excerpt

INTRODUCTION: Elagolix is a novel, orally active, non-peptide, competitive gonadotropin-releasing hormone (GnRH) receptor antagonist in development for the management of endometriosis with associated pain and heavy menstrual bleeding due to uterine fibroids. The pharmacokinetics of elagolix have been well-characterized in phase I studies; however, elagolix population pharmacokinetics have not been previously...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Clinical Trials, Phase I as Topic
Share to Clinical Trials, Phase III as Topic

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Endometriosis

Share to Inactivation, Metabolic

Share to Liver-Specific Organic Anion Transporter 1

Share to Premenopause

Share to Pyrimidines

Share to Receptors, LHRH

Source

Identifiers

PMID: 29476499
DOI: 10.1007/s40262-018-0629-6

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Population Pharmacokinetics of Elagolix in Healthy Women and Women with Endometriosis.PMID 29476499Read ↗

Population Pharmacokinetic Analysis of Follicle-Stimulating Hormone During Ovarian Stimulation: Relation with Weight, Prolactin and Gene Polymorphism in THADA and ADIPOQ.Semantic proximity Read ↗

Exploring the Population Pharmacokinetic and Pharmacogenetics Characteristics of Flurbiprofen Isomers in Selective Joint Replacement Patients with Postoperative Pain.Semantic proximity Read ↗

Considerations on implementation of the newest treatment for symptomatic uterine fibroids: oral GnRH antagonists.Semantic proximity Read ↗

Population pharmacokinetics of ABT-767 in BRCA1 or BRCA2 mutation carriers with advanced solid tumors or in subjects with high grade serous ovarian, primary peritoneal or fallopian tube cancer.Semantic proximity Read ↗

Pharmacokinetics of Eltrombopag in Healthy Chinese Subjects and Effect of Sex and Genetic Polymorphism on its Pharmacokinetic and Pharmacodynamic Variability.Semantic proximity Read ↗

Population pharmacokinetic modeling of tamoxifen and its active metabolite endoxifen in healthy volunteers of African ancestry genotyped for CYP2B6, CYP2C9, CYP2C19, CYP2D6, CYP3A4 and CYP3A5.Semantic proximity Read ↗

Real Life Data for Relugolix/Estradiol/Norethisteroneacetate Treatment for Chronic Pelvic Pain in Endometriosis PatientsSemantic proximity Read ↗

Improving Understanding of Fexofenadine Pharmacokinetics to Assess Pgp Phenotypic Activity in Older Adult Patients Using Population Pharmacokinetic Modeling.Semantic proximity Read ↗

Effects of elagolix on the pharmacokinetics of omeprazole and its metabolites in healthy premenopausal women.Semantic proximity Read ↗

Estrogen profile- and pharmacogenetics-based lamotrigine dosing regimen optimization: Recommendations for pregnant women with epilepsy.Semantic proximity Read ↗

PharmGKB summary: citalopram pharmacokinetics pathway.Semantic proximity Read ↗

Population pharmacokinetics of omeprazole in obese and normal-weight adults.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.